BPC-157 5mg

BPC-157, or Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protein found in human gastric juice. This peptide has been studied for its potential regenerative effects on various tissues. Research indicates that BPC-157 may play a role in promoting healing processes, particularly in tissues with limited blood supply, such as tendons and ligaments.

BPC-157 Peptide Research

Healing, Protection, and Therapeutic Potential

Wound Healing and Fibroblast Activation

BPC-157 naturally functions in the gastrointestinal (GI) tract by maintaining the integrity of the mucosal barrier, protecting tissues from digestive compounds like gastric acid and bile. This peptide promotes wound healing by recruiting fibroblasts, cells critical for repairing tissue through the production of extracellular matrix proteins such as collagen, fibrin, and elastin. BPC-157 enhances fibroblast proliferation and migration in both cell cultures and living organisms in a dose-dependent manner.

Vascular Growth and Collateralization

BPC-157 is a powerful angiogenic factor that stimulates endothelial cell growth and proliferation. Research in rats demonstrates its ability to accelerate collateral blood vessel growth, particularly in ischemic conditions. This vascularization effect extends beyond the GI tract to cardiovascular, neurological, and muscle tissues, offering potential therapies for stroke, heart attack, and ischemic injury. Mechanistically, BPC-157 activates VEGFR2, a receptor involved in nitric oxide signaling, essential for endothelial cell longevity and proliferation. Its ability to promote vascular “running” — the growth of blood vessels around blockages — suggests future oral therapies could reduce the need for invasive procedures like stenting or bypass surgery.

Tendon, Ligament, and Bone Healing

Due to its dual action on fibroblasts and blood vessels, BPC-157 effectively promotes healing in connective tissues, which typically suffer from poor blood supply. Studies in rats show increased fibroblast density and collateralization in tendon, ligament, and bone injuries, outperforming other growth factors such as bFGF, EGF, and VEGF. BPC-157 stimulates F-actin formation, crucial for cell migration, and increases phosphorylation of key proteins paxillin and FAK involved in cell movement.

Antioxidant Properties

BPC-157 exhibits strong antioxidant effects by neutralizing oxidative stress markers such as nitric oxide and malondialdehyde (MDA). It reduces reactive oxygen species production in the GI tract, which contributes to its protective and healing properties. Research using modified Lactococcus lactis bacteria shows enhanced delivery and increased peptide levels in cell cultures.

Protection Against Drug Side Effects

Many pharmaceuticals are limited by their side effects. For example, NSAIDs increase risks of gastric bleeding and heart attacks, restricting long-term use. BPC-157 has demonstrated the ability to counteract adverse effects from NSAIDs, psychiatric medications, and heart drugs. It protects against gastrointestinal side effects and prevents serious cardiac conditions like QTc prolongation, which can cause fatal arrhythmias. It also mitigates severe side effects of psychiatric drugs such as catalepsy and sensory disturbances, potentially improving medication adherence in psychiatric patients.

Application in Honey Bee Colony Collapse Disorder (CCD)

CCD causes rapid decline and destruction of honey bee colonies, partly due to fungal infections like Nosema ceranae in bee guts. Supplementing bee food with BPC-157 reduces fungal damage and improves hive survival in natural field trials, marking the first significant oral treatment to help protect this crucial pollinator species.

Research Applications

BPC-157 has been primarily utilized in scientific studies focusing on:

• Tendon and Ligament Repair: Investigating its potential to accelerate the healing of tendon and ligament injuries.
• Muscle Regeneration: Exploring its effects on muscle tissue repair and regeneration.
• Bone Healing: Assessing its role in promoting bone repair and healing processes.
• Gastrointestinal Health: Studying its potential benefits in healing gastric ulcers and other gastrointestinal injuries.
• Neuroprotection: Examining its effects on nerve tissue repair and protection.

These applications are part of ongoing research aimed at understanding the broader implications of BPC-157 in various biological processes.

Product Specifications

• Form: Lyophilized (freeze-dried) powder for reconstitution.
• Purity: 99% or higher, ensuring high-quality material for research purposes.
• Packaging: Each package contains 1 vial, each with 5 milligrams of BPC-157.

This product is intended strictly for laboratory research and is not approved for human consumption.

Referenced Citations

• Huang T. et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo,” Drug Des. Devel. Ther., 2015;9:2485-2499. 
• Drmic D. et al., “Counteraction of perforated cecum lesions in rats: Effects of BPC 157,” World J. Gastroenterol., 2018;24(48):5462-5476. 
• Amic F. et al., “Bypassing major venous occlusion with BPC 157,” World J. Gastroenterol., 2018;24(47):5366-5378. 
• Duzel A. et al., “BPC 157 in treatment of colitis and ischemia in rats,” World J. Gastroenterol., 2017;23(48):8465-8488. 
• Vukojević J. et al., “Rat inferior caval vein ligature and BPC 157 insights,” Vascul. Pharmacol., 2018;106:54-66. 
• D. Drmic et al., “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME,” World J. Gastroenterol., vol. 23, no. 29, pp. 5304-5312, Aug. 2017. 
• M.-J. Hsien et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med. Berl. Ger., vol. 95, no. 3, pp. 323-333, 2017. 
• Z. Grabarevic et al., “The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks,” J. Physiol. Paris, vol. 91, no. 3-5, pp. 139-149, Oct. 1997. 
• P. Sikirc et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1990-2001, 2018. 
• S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1972-1989, 2018. 
• C.-H. Chang et al., “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774-780, Oct. 2010. 
• Y.-L. Hu et al., “FAK and paxilin dynamics at focal adhesions in the protrusions of migrating cells,” Sci. Rep., vol. 4, p. 6024, Aug. 2014. 
• K. Skrlec et al., “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities,” Appl. Microbiol. Biotechnol., vol. 102, no. 23, pp. 10103-10117, Dec. 2018. 
• D. Strinic et al., “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats,” Life Sci., vol. 186, pp. 66-79, Oct. 2017. 
• N. Jelovac et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats,” Eur. J. Pharmacol., vol. 379, no. 1, pp. 19-31, Aug. 1999 .
• J. Tlak Gajger et al., “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” J. Vet. Pharmacol. Ther., vol. 41, no. 4, pp. 614-621, Aug. 2018 .